

Avsola (infliximab-axxq)
Inflectra (infliximab-dyyb)
Infliximab
Remicade (inflixima)
Renflexis (infliximab-adba)
Effective 10/01/2024

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Notes	These agents are also available on the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		

Overview

FDA approved indications:

Ankylosing Spondylitis: Avsola, Inflectra, infliximab, Remicade, Renflexis

Crohn's Disease, Moderate-to-severe: Avsola, Inflectra, infliximab, Remicade, Renflexis

Crohn's Disease (including fistulizing disease), Moderate-to-severe: Avsola, Inflectra, infliximab, Remicade, Renflexis

Plaque Psoriasis, Moderate-to-severe: Avsola, Inflectra, infliximab, Remicade, Renflexis

Psoriatic Arthritis: Avsola, Inflectra, infliximab, Remicade, Renflexis,

Rheumatoid Arthritis (RA), Moderate-to-severe: Avsola, Inflectra, infliximab, Remicade, Renflexis

Ulcerative colitis, Moderate-to-Severe: Avsola, Inflectra, infliximab, Remicade, Renflexis,

Coverage Guidelines

Authorizations requests will be reviewed on a case by case basis for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

Moderate to severe rheumatoid arthritis

1. Diagnosis of moderate to severe rheumatoid arthritis
2. Member meets **ONE** of the following:
 - a. Paid claim or provider attestation of inadequate response or adverse reaction to **ONE** traditional DMARD or contraindication to traditional DMARDs

- b. Paid claim or provider attestation of inadequate response or adverse reaction to **ONE** biologic DMARD that is FDA-approved for the requested indication
- 3. Appropriate dosing[†]
- 4. Provider provides clinical rationale for use of the requested agent instead of Enbrel and Humira

Psoriatic arthritis (PsA)

- 1. Diagnosis of psoriatic arthritis
- 2. Appropriate dosing[†]
- 3. Provider provides clinical rationale for use of the requested agent instead of Enbrel and Humira

Ankylosing Spondylitis

- 1. Diagnosis of ankylosing spondylitis
- 2. Paid claims or physician attestation of inadequate response or adverse reaction to **TWO** or contraindication to **ALL** NSAIDs
- 3. Appropriate dosing[†]
- 4. Provider provides clinical rationale for use of the requested agent instead of Enbrel and Humira

Moderate to severe plaque psoriasis

- 1. Diagnosis of moderate to severe plaque psoriasis
- 2. Member meets **ONE** of the following:
 - a. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** or contraindication to **ALL** conventional therapies: (see appendix)
 - a. topical agent
 - b. phototherapy
 - c. systemic agent
 - b. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** biologic DMARD that is FDA-approved for plaque psoriasis
- 3. Appropriate dosing[†]
- 4. Provider provides clinical rationale for use of the requested agent instead of Enbrel and Humira

Moderate to severe Crohn's Disease

- 1. Diagnosis of moderate to severe Crohn's disease
- 2. Appropriate dosing[†]
- 3. Provider provides clinical rationale for use of the requested agent instead of Humira

Fistulizing Crohn's disease

- 1. Diagnosis of fistulizing Crohn's disease
- 2. Appropriate dosing[†]

Moderate-to-severe ulcerative colitis

- 1. Diagnosis of moderate to severe ulcerative colitis
- 2. Appropriate dosing[†]
- 3. Provider provides clinical rationale for use of the requested agent instead of Humira

† Requests for more frequent or higher doses - see Appendix

Off-Label Indications

Behçet's Disease (BD)



1. Diagnosis of Behçet's Disease
2. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** or contraindication to **ALL** topical corticosteroids
3. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** or contraindication to **ALL** systemic corticosteroids
4. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** or contraindication to **ALL** of the following:
 - a. azathioprine
 - b. colchicine
 - c. cyclophosphamide
 - d. cyclosporine
 - e. methotrexate
 - f. Otezla(apremilast)
5. Clinical rationale for use of the requested agent instead of Enbrel and Humira

Moderate to severe hidradenitis suppurativa

1. Diagnosis of moderate to severe hidradenitis suppurativa (**Hurley Stage II and Hurley Stage III disease**)
2. Paid claims within 6 months or physician attestation of inadequate response or adverse reaction to **ONE** or contraindication to **ALL** oral antibiotics (e.g. rifampin, clindamycin, tetracycline, doxycycline, minocycline)
3. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to Humira(adalimumab)

Neurologic sarcoidosis

1. Diagnosis of neurologic sarcoidosis
2. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** systemic corticosteroid or contraindication to **ALL** systemic corticosteroids
3. Paid claims or physician attestation of an inadequate response or adverse reaction to **TWO** or a contraindication to **ALL** of the following:
 - a. azathioprine
 - b. cyclophosphamide
 - c. leflunomide
 - d. methotrexate
 - e. mycophenolate mofetil

Pulmonary Sarcoidosis

1. Diagnosis of pulmonary sarcoidosis
2. Inadequate response, adverse reaction, or contraindication to **BOTH** of the following:
 - a. Systemic glucocorticoids
 - b. **ONE** traditional DMARD (methotrexate, azathioprine, leflunomide, or mycophenolate)
3. Prescriber must also document **ONE** of the following:
 - a. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to Humira(adalimumab)
 - b. Clinical rationale for use of Avsola (infliximab-axxq), unbranded infliximab, Remicade (infliximab) Inflectra(infliximab-dyyb), or Renflexis (infliximab-abda) instead of Humira (adalimumab)

Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome (SAPHO)

1. Diagnosis of SAPHO



2. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** NSAID or contraindication to **ALL** NSAIDs
3. Paid claims or physician attestation of inadequate response or adverse reaction to **ONE** systemic corticosteroid or contraindication to **ALL** systemic corticosteroids
4. Clinical rationale for use of the requested agent instead of Enbrel and Humira

Scleritis

1. Diagnosis of scleritis
2. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to **BOTH** of the following:
 - a. ophthalmic (topical), oral or injectable glucocorticoids
 - b. oral or injectable immunosuppressive therapy (e.g., azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, and cyclophosphamide)

Takayasu Arteritis (TAK)

1. Diagnosis of Takayasu arteritis
2. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to **BOTH** of the following:
 - a. systemic glucocorticoids
 - b. **ONE** traditional DMARD (methotrexate, azathioprine, leflunomide, or mycophenolate)
3. Prescriber must also document **ONE** of the following:
 - a. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to Humira(adalimumab) and Enbrel(etanercept)
 - b. Clinical rationale for use of Avsola(infliximab-axxq), unbranded infliximab, Remicade(infliximab) Inflectra(infliximab-dyyb), or Renflexis(infliximab-abda) instead of Humira(adalimumab) and Enbrel(etanercept)

Uveitis

1. Diagnosis of uveitis
2. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to **BOTH** of the following:
 - a. Ophthalmic (topical), oral or injectable glucocorticoids
 - b. Oral or injectable immunosuppressive therapy (e.g., azathioprine, mycophenolate, methotrexate, cyclosporine, tacrolimus, and cyclophosphamide)
3. **ONE** of the following:
 - a. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to Humira(adalimumab)
 - b. Clinical rationale for use of the requested agent instead of Humira(adalimumab)

Continuation of Therapy

Resubmission by prescriber will infer a positive response to therapy and request can be recertified if dosing is appropriate.

Limitations

1. Initial authorizations will be granted for:
 - a. Plaque psoriasis and Off Label indications: 3 months
 - b. All other indications: 6 months
2. Reauthorizations for all diagnoses will be granted for 12 months



Appendix A. Examples of Traditional DMARDs

Traditional DMARDs*	
azathioprine	methotrexate*
cyclosporine	sulfasalazine*
hydroxychloroquine*	thalidomide
leflunomide	
If a member has a contraindication to ALL of the most commonly used traditional DMARDs* (methotrexate, sulfasalazine, and hydroxychloroquine), a trial with a traditional DMARD may be bypassed.	

Appendix B. Conventional Therapies for Plaque Psoriasis

Conventional Treatment Lines	Agents Used
Topical Agents	emollients, keratolytics, corticosteroids, coal tar, anthralin, calcipotriene, tazarotene, calcitriol, calcineurin inhibitors
Systemic Agents	Traditional DMARDs: methotrexate, apremilast, acitretin,
Phototherapy	ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA), narrow band UV-B (NUVB)

Appendix C. More frequent/Higher doses

Requests more frequent or higher doses of injectable biologics, may be approved if **ALL** of the following is provided:

1. Documentation of severe disease
2. **ONE** of the following:
 - a. Inadequate response or adverse reaction to **ONE** other injectable biologic which is FDA-approved for the requested indication*
 - b. Contraindication to **ALL** other injectable biologics which are FDA-approved for the requested indication
3. Documented partial response to FDA-approved dosing of current biologic therapy
4. Documentation of specialist consult for the requested indication

*A trial with another injectable biologic may be bypassed if:

- The requested regimen is Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), infliximab, Remicade (infliximab), or Renflexis (infliximab-abda) for Crohn's disease or ulcerative colitis and the request documents low drug levels and no/low antibodies. The recommended trough level for infliximab is greater than or equal to 5 mcg/mL in patients with inflammatory bowel disease.
- The requested regimen is Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), unbranded infliximab, Remicade (infliximab), or Renflexis (infliximab-abda) and the request documents that standard-weight based dosing would not be adequate in a pediatric member.

References

1. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; June 2018.
2. Renflexis (infliximab) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme; November 2017.
3. Inflectra (infliximab dyyb) [prescribing information]. New York, NY: Pfizer; November 2017
4. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther*. 2016;18:82.[\[PubMed 27038608\]](https://pubmed.ncbi.nlm.nih.gov/27038608/)



5. Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther*. 2016;18:25. [\[PubMed 26795209\]](#)
6. van der Heijde D, Ramiro S, Landewe R, et al. 2016 Update of the international ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017;0:1-14.
7. Meyer A, Rudant J, Drouin J, et al. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. *Ann Intern Med* 2019; 170:99.
8. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum*. 2008;59(6):762-784.
9. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017;0:1-18.
10. [Singh JA](#), [Saag KG](#), [Bridges SL Jr](#), et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1)1-26.
11. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
12. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies; 2015 update. *Ann Rheum Dis*. 2016;75(3):499-510.
13. Peluso R, Lervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritis patients. *Clin Rheumatol*. 2014 May 8. [Epub ahead of print].
14. S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. *Arthritis & Rheumatism*. 2013;65:2499-2512.
15. [Ward MM](#), [Deodhar A](#), [Akl EA](#), et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. [Arthritis Rheumatol](#). 2015: 10.1002/art.39298. [Epub ahead of print].
16. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2001; 18:70
17. Della Rossa A, Tavoni A, Merlini G, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? *Rheumatology (Oxford)* 2005; 44:1074
18. Mooij JE, van Rappard DC, Mekkes JR. Six patients with pyoderma gangrenosum successfully treated with infliximab. *Int J Dermatol* 2013; 52:1418
19. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. *Arthritis Rheum* 2005; 52:2478
20. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol* 2010; 62:205
21. Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. *Gut* 2017. Avsola (infliximab-axxq) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2019.

Review History



11/17/2021 – Created and Reviewed Nov P&T; switched from CVS SGM to Custom criteria; matched with MH UPPL. Effective 01/01/2022

05/18/2022 – Updated and Reviewed for May P&T; Matched MH UPPL. Avsola and unbranded infliximab as preferred formulations of infliximab. A trial with other infliximab agents would require a step through one of these formulations. As unbranded infliximab is an authorized biosimilar to Remicade, a request for the latter agent would require a trial with unbranded infliximab. UC criteria: Requirement of provider specialty was removed, required trial with one anti-TNF agent and Entyvio was removed, and “Member is not currently receiving concomitant therapy with immunomodulators or biologic agents” was removed. Appendix C: Off label indications was updated. Renamed Appendix B to “Conventional Therapies for Plaque Psoriasis”. Effective 07/01/2022.

06/22/2022 - Reviewed and updated for June P&T; matched MH UPPL. Added off label indication of neurologic sarcoidosis to Appendix section. Effective 08/01/2022.

11/16/2022 – Reviewed and updated for Nov P&T; matched MH. Clinical rationale for use of Inflectra or Renflexis instead of unbranded infliximab or Avsola updated to include clinical rationale instead of both agents. Added criteria for off label use in Neurologic Sarcoidosis. Effective 11/01/2022

01/11/2023 – Reviewed and updated for Jan P&T. Appropriate diagnosis was replaced with a specific indication throughout. Off-label indications added for: Behcet's disease, HS, neurologic sarcoidosis, pulmonary sarcoidosis, SAPHO, scleritis, TAK, uveitis. Added language regarding stability of requested medication for new members: Requests for Avsola and unbranded infliximab that document stability for any FDA-approved indication at an FDA-approved dose can be approved. Requests for Inflectra or Renflexis that document stability can be approved without documentation of failed trials with the preferred infliximab agents for ankylosing spondylitis or Crohn’s disease. Clarified initial approval durations. Effective 3/1/23.

05/10/23 – Reviewed and updated for P&T. The appendix for More Frequent or Higher Doses of Injectable Biologics was updated to allow more aggressive dosing of infliximab products to be approved if the request documents concern that standard-weight based dosing would not be adequate in a pediatric member. Separating Rx vs MB policies and removed preferred product requirement. Effective 6/5/23.

09/11/24 – Reviewed and updated for P&T. Removed excerpt regarding “new members who are currently stable” as it no longer pertains to policy (no preferred infliximab agents) and was considered repetitive. Effective 10/1/24

